Orforglipron

China [CN]

I. Basic Information

Generic Name: Orforglipron

Development Code: LY-3502970, OWL833

Original Developer: Chugai Pharmaceutical, licensed to Eli Lilly for global development in 2018

Marketing Schedule:

USA: Submitted marketing application for obesity/overweight in December 2025, expected approval in April 2026

China: NMPA accepted marketing application for type 2 diabetes + obesity in January 2026

Global: Planned to cover 40+ countries within 2 years

II. Mechanism of Action (Simplified Version)

Activates GLP-1 receptors in the body, achieving 4 Key Benefits:

Blood Sugar Control: Promotes insulin secretion and inhibits glucagon when blood sugar is high, preventing hypoglycemia.

Weight Loss: Delays gastric emptying and suppresses appetite, reducing hunger.

Heart Health: Improves blood pressure and blood lipids, reducing cardiovascular risk.

Convenience: Oral small molecule formula, eliminating the need for injections.

III. Core Advantages (Different from Smegglutinin/Telbopeptide)

1. Revolutionary Dosing Experience (Biggest Highlight)

Operated once daily, no injection or refrigeration required.

No dietary/hydration restrictions (take at any time), compared to oral Smegglutinin which requires fasting + 30 minutes of fasting.

Significantly improves long-term adherence, covering more patients who are resistant to injections.

2. Efficacy Data (Phase III Clinical Trial)

Weight Loss (Obese/Overweight): 36mg x 72 weeks, average weight loss 12.4kg (10.5%); 59.6% of patients lost ≥10%.

Blood Sugar Control (Type 2 Diabetes): 36mg x 72 weeks, average HbA1c reduction 2.2%, 75% Patients achieving target weight loss ≤6.5%

Head-to-head: Compared to oral semaglutide, it offers superior weight loss and blood sugar control with fewer gastrointestinal side effects.

3. Clinical Value

Switching from injectable GLP-1 (semaglutide/telbottide) can maintain 95%–80% of the weight loss effect.

More stable production/storage and transportation, no cold chain dependence, and higher accessibility.

IV. Indications (Investigational/Soon to be Approved)

Type 2 diabetes (monotherapy/combination with metformin)

Obesity/Overweight (BMI ≥ 27, with metabolic comorbidities)

Potential expansion: NASH, hypertension, obstructive sleep apnea

V. Usage and Safety

Initial dose: 1 mg/day, increasing every 4 weeks (to reduce nausea/diarrhea)

Maintenance dose: Usually 36 mg/day

Main side effects: Mild nausea, diarrhea, decreased appetite, initially appearing and resolving over time

Contraindications: Allergy, pregnancy/lactation, family history/personal history of medullary thyroid carcinoma